In the past week, AEON stock has gone up by 11.34%, with a monthly gain of 24.80% and a quarterly plunge of -92.89%. The volatility ratio for the week is 7.10%, and the volatility levels for the last 30 days are 5.59% for AEON Biopharma Inc The simple moving average for the past 20 days is 14.27% for AEON’s stock, with a -98.36% simple moving average for the past 200 days.
Is It Worth Investing in AEON Biopharma Inc (AMEX: AEON) Right Now?
The price-to-earnings ratio for AEON Biopharma Inc (AMEX: AEON) is above average at 0.00x, Company’s 36-month beta value is 0.45.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AEON is 10.83M, and currently, short sellers hold a 0.64% ratio of that floaft. The average trading volume of AEON on May 23, 2025 was 3.25M shares.
AEON) stock’s latest price update
AEON Biopharma Inc (AMEX: AEON)’s stock price has soared by 12.96 in relation to previous closing price of 0.49. Nevertheless, the company has seen a gain of 11.34% in its stock price over the last five trading days. globenewswire.com reported 2025-05-19 that IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that Rob Bancroft, AEON’s President and Chief Executive Officer, will present a corporate overview at the Aegis Capital Corp. 2025 Virtual Conference on Wednesday, May 21st at 7:00 a.m. PT / 10:00 am ET.
Analysts’ Opinion of AEON
Many brokerage firms have already submitted their reports for AEON stocks, with H.C. Wainwright repeating the rating for AEON by listing it as a “Buy.” The predicted price for AEON in the upcoming period, according to H.C. Wainwright is $18 based on the research report published on August 18, 2023 of the previous year 2023.
AEON Trading at 5.81% from the 50-Day Moving Average
After a stumble in the market that brought AEON to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.80% of loss for the given period.
Volatility was left at 5.59%, however, over the last 30 days, the volatility rate increased by 7.10%, as shares surge +19.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.43% lower at present.
During the last 5 trading sessions, AEON rose by +11.34%, which changed the moving average for the period of 200-days by -99.27% in comparison to the 20-day moving average, which settled at $0.4804. In addition, AEON Biopharma Inc saw -98.59% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AEON starting from FISCHER JOST, who purchase 60,000 shares at the price of $0.51 back on May 20 ’25. After this action, FISCHER JOST now owns 206,785 shares of AEON Biopharma Inc, valued at $30,360 using the latest closing price.
FISCHER JOST, the Director of AEON Biopharma Inc, purchase 50,000 shares at $0.50 during a trade that took place back on May 19 ’25, which means that FISCHER JOST is holding 146,785 shares at $24,940 based on the most recent closing price.
Stock Fundamentals for AEON
The total capital return value is set at -6.63.
Based on AEON Biopharma Inc (AEON), the company’s capital structure generated -0.83 points at debt to capital in total, while cash flow to debt ratio is standing at -1.57.
Currently, EBITDA for the company is -27.73 million with net debt to EBITDA at -0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.43.
Conclusion
In a nutshell, AEON Biopharma Inc (AEON) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
